Moncef SlaouiScientific Head at Operation Warp Speed
Moncef is a Partner at Medicxi and has been with the firm since September 2017. He is currently dedicating his attention and focus as Chief Scientist for Operation Warp Speed - the fast track programme for the development of a COVID-19 vaccine and therapeutic in the US.
Prior to Medicxi, Moncef was GlaxoSmithKline’s Head of Pharmaceutical R&D and Chairman of its Vaccines division. From this leadership role, Moncef spearheaded a profound overhaul of GSK's pharmaceutical R&D, resulting in a substantial improvement in productivity, a late-stage pipeline comprising more than 30 phase 3 programmes and a totally redesigned discovery organisation comprising 38 highly focused and accountable Discovery Performance Units. During his career at GSK, he also headed the development of a robust vaccines pipeline, including Rotarix to prevent infantile gastroenteritis, Synflorix to prevent pneumococcal disease and Cervarix to prevent cervical cancer.
Outside of his role at Medicxi, Moncef is chairman of the board at Galvani Bioelectronics and chairman of the board at Vaxcyte.
Moncef received a PhD in Molecular Biology and Immunology from the Université Libre de Bruxelles, Belgium and completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston. He was a professor of Immunology at the University of Mons, Belgium and has authored more than 100 scientific papers and presentations. A citizen of Morocco, Belgium and the USA, he is fluent in English, French and Arabic.